Literature DB >> 9249469

SR Ca(2+)-ATPase activity and expression in ventricular myocardium of dogs with heart failure.

R C Gupta1, H Shimoyama, M Tanimura, R Nair, M Lesch, H N Sabbah.   

Abstract

The purpose of this study was to examine the activity and expression of sarcoplasmic reticulum (SR) Ca(2+)-ATPase in left ventricular (LV) myocardium of dogs with chronic heart failure (HF). LV and right ventricular (RV) tissue specimens were obtained from six normal (NL) control dogs and six dogs with chronic HF (LV ejection fraction, 23 +/- 2%) produced by multiple sequential intracoronary microembolizations. Thapsigargin-sensitive Ca(2+)-ATPase activity was measured in isolated SR membrane fractions prepared from LV and RV myocardium. Ca(2+)-ATPase expression, using a specific dog myocardium monoclonal antibody, was measured in sodium dodecyl sulfate (SDS) extract prepared from LV and RV myocardium. Ca(2+)-ATPase activity in both ventricles of NL or HF dogs increased with increasing Ca2+ concentration and reached a plateau at 3 microM Ca2+. The maximal velocity (Vmax, mumol Pi released.min-1.mg-1) of Ca(2+)-ATPase activity was significantly lower in LV of HF dogs compared with NL (0.15 +/- 0.01 vs. 0.23 +/- 0.01, P < 0.05), whereas the affinity of the Ca2+ pump for Ca2+ was unchanged. LV tissue levels of Ca(2+)-ATPase (densitometric units/5 micrograms noncollagen protein) were also significantly lower in LV myocardium of HF dogs compared with NL (3.52 +/- 0.43 vs. 5.53 +/- 0.47, P < 0.05). No significant differences in Ca(2+)-ATPase activity or expression were observed in RV myocardium of HF dogs compared with NL. We conclude that SR Ca(2+)-ATPase activity and protein levels are reduced in LV myocardium of dogs with chronic HF. This abnormality of the SR Ca2+ pump of the failed LV can result in impaired Ca2+ uptake and ultimately to Ca2+ overload and global LV dysfunction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249469     DOI: 10.1152/ajpheart.1997.273.1.H12

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  12 in total

1.  Pathophysiology of coronary microembolisation.

Authors:  G Heusch; R Schulz
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

Review 2.  Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure.

Authors:  Mihai Gheorghiade; Muthiah Vaduganathan; Andrew Ambrosy; Michael Böhm; Umberto Campia; John G F Cleland; Francesco Fedele; Gregg C Fonarow; Aldo P Maggioni; Alexandre Mebazaa; Mandeep Mehra; Marco Metra; Savina Nodari; Peter S Pang; Piotr Ponikowski; Hani N Sabbah; Michel Komajda; Javed Butler
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

3.  Differences in Left Versus Right Ventricular Electrophysiological Properties in Cardiac Dysfunction and Arrhythmogenesis.

Authors:  Cristina E Molina; Jordi Heijman; Dobromir Dobrev
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

Review 4.  Improvement of cardiac sarcoplasmic reticulum calcium cycling in dogs with heart failure following long-term therapy with the Acorn Cardiac Support Device.

Authors:  Ramesh C Gupta; Sudhish Mishra; Sharad Rastogi; Victor G Sharov; Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2005-06       Impact factor: 4.214

5.  Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats.

Authors:  Ramesh C Gupta; Sudhish Mishra; Xiao-Ping Yang; Hani N Sabbah
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

6.  Myocardial transfection with naked DNA plasmid encoding hepatocyte growth factor prevents the progression of heart failure in dogs.

Authors:  Sharad Rastogi; Mayra Guerrero; Mengjun Wang; Itamar Ilsar; Michael S Sabbah; Ramesh C Gupta; Hani N Sabbah
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-07       Impact factor: 4.733

7.  MET-88, a gamma-butyrobetaine hydroxylase inhibitor, improves cardiac SR Ca2+ uptake activity in rats with congestive heart failure following myocardial infarction.

Authors:  Y Hayashi; H Ishida; M Hoshiai; K Hoshiai; T Kirimoto; T Kanno; M Nakano; K Tajima; H Miyake; N Matsuura; H Nakazawa
Journal:  Mol Cell Biochem       Date:  2000-06       Impact factor: 3.396

Review 8.  Modeling heart failure in animal models for novel drug discovery and development.

Authors:  Paul M L Janssen; Mohammad T Elnakish
Journal:  Expert Opin Drug Discov       Date:  2019-03-12       Impact factor: 6.098

Review 9.  Biologic rationale for the use of beta-blockers in the treatment of heart failure.

Authors:  Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2004-04       Impact factor: 4.214

10.  Animal models of cardiac disease and stem cell therapy.

Authors:  Lailiang Ou; Wenzhong Li; Yi Liu; Yue Zhang; Shen Jie; Deling Kong; Gustav Steinhoff; Nan Ma
Journal:  Open Cardiovasc Med J       Date:  2010-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.